Study aim: Investigating the effect of curcumin supplementation on improving inflammatory parameters and regulating coagulation factors in patients with covid-19 Design: The study is a phase-3 randomized double-blind clinical trial, in which people with covid-19 will be divided into two groups with 30 people taking curcumin supplements and 30 people taking placebo. Random allocation software will be used to randomize samples into two treatment and placebo groups. Settings and conduct: This study is a phase-3 double-blind clinical trial. People with covid-19 who will refer to the Prophet's hospital will be selected. Random Allocation software will be used to randomize the sample to two treatment groups and placebo in Random Allocation software. Capsules will be stored and given in similar packages (with A and B marks) to patients by an out-of-study person. Participants/Inclusion and exclusion criteria: Inclusion criteria: Covid-19 approved patients with PCR or CT-SCAN testing, satisfaction to participation, Aged 18-70 years. Exclusion criteria: history of susceptibility to jaundice, biliary disorders, cardiovascular disorders and recipients of anticoagulants. Intervention groups: 1- Patients receiving curcumin supplementation 2- Patients receiving placebo Main outcome variables: ct-scan findings; Hospitalization duration; CBC; LDH; PT; PTT; D-DIMER; BUN / CR.